Understand the source comparison
MASH vs GLP-1 Monotherapy Research: Comparison
Primary Endpoint MASH resolution without fibrosis worsening (62.9% at 4.8mg, 48 weeks) MASH resolution without fibrosis worsening (~40–50% at 2.4mg, variable trial designs) MASH resolution without fibrosis worsening (~55–60% at 10–15mg, 52 weeks) Dual agonists
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Endpoint
- MASH resolution without fibrosis worsening (62.9% at 4.8mg, 48 weeks)
- MASH resolution without fibrosis worsening (~40–50% at 2.4mg, variable trial designs)
- MASH resolution without fibrosis worsening (~55–60% at 10–15mg, 52 weeks)
- Dual agonists consistently outperform GLP-1 monotherapy on histological endpoints. The GIP component appears critical for inflammation resolution
- Fibrosis Improvement Rate
- 51% achieved ≥1 stage improvement at 4.8mg dose
- 30–35% in most trials
- 45–50% in ongoing trials
- Fibrosis regression is the harder endpoint. Survodutide and tirzepatide show meaningful benefit, semaglutide shows modest improvement
- Hepatic Fat Reduction (MRI-PDFF)
- 71% relative reduction at 48 weeks
- 50–60% relative reduction
- 65–70% relative reduction
- All three agents substantially reduce hepatic steatosis. This appears to be a class effect of incretin agonists
- Weight Loss (Secondary)
- 12–15% body weight reduction at 48 weeks
- 10–12% body weight reduction at similar durations
- 15–20% body weight reduction
- Weight loss correlates with MASH improvement but is not the sole driver. Direct hepatic mechanisms matter
- GI Adverse Event Rate
- 40–50% (nausea, diarrhoea) during titration
- 35–45% during titration
- 45–55% during titration
- GI side effects remain the primary tolerability barrier across all GLP-1-based therapies. Dose escalation protocols mitigate but don't eliminate this
- Dual GLP-1/GIP agonism produces superior MASH resolution and fibrosis improvement compared to GLP-1 monotherapy. The mechanism isn't just additive weight loss. GIP receptor engagement appears to modulate hepatic inflammation directly. Trials like SYNERGY-NASH (survodutide Phase 3) and others will clarify whether this translates to reduced cirrhosis progression and liver-related mortality over multi-year follow-up.